



INTERNATIONAL GENERIC AND  
BIOSIMILAR MEDICINES ASSOCIATION

Info: [info@igbamedicines.org](mailto:info@igbamedicines.org)

## Jonathan Kimball takes over the position of IGBA Chair

Geneva, 12 January 2023

For immediate release

[The International Generic and Biosimilar Medicines Association](#) (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that [Jonathan Kimball](#), Vice President of Trade and International Affairs of the Association for Accessible Medicines (AAM), Vice-Chair IGBA and Vice Chair of the IGBA International Trade and Intellectual Property Committee in 2022, is taking over the position of IGBA Chair for 2023 from [Vivian Frittelli](#), Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM). [Adrian van den Hoven](#), Director General of Medicines for Europe, steps in as IGBA Vice-Chair.

*“2022 marked the establishment of the [IGBA CEO Advisory Committee](#), composed of 14 Leaders of the major global generic and biosimilar medicines companies. This Committee provides a forum for industry leaders to discuss broad, strategic issues, and to position the industry on a range of critical policy issues and allows engaging directly as a collective with the Heads of global institutions”, commented the outgoing IGBA Chair, Vivian Frittelli. “A major milestone for IGBA was also achieved when it was admitted [as a non-State actor in official relations with the WHO](#). Furthermore, IGBA joined the [Access to Oncology Medicines \(ATOM\) Coalition](#) and the [Fight the Fakes Alliance](#), demonstrating our industry’s continued commitment to worldwide access to safe and quality-assured medicines”, Frittelli concluded.*

*“In the course of 2022, IGBA continued to strongly support the more important than ever scientific harmonization process within the [International Council for Harmonization \(ICH\)](#) and launched an increasingly successful third version of the [Global Biosimilars Week \(GBW\)](#) social media campaign, led by [Erica Klinger](#), Senior Director, Marketing, AAM. The GBW provided also an opportunity to release a new IGBA White Paper, entitled [Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline](#). This paper was developed by the IGBA Biosimilars Committee, under the strong leadership of [Erika Satterwhite](#) and [Julie Maréchal-Jamil](#), who passed on the baton to [Gillian Woollett](#), VP, Head Regulatory, Strategy and Policy, Samsung Bioepis, US, and [Giuseppe Randazzo](#), VP of Sciences and Regulatory Affairs, AAM”, commented Suzette Kox, IGBA Secretary General. “After leading the International Trade and Intellectual Property Committee for many years, [Jody Cox](#), Vice President, Federal and International Affairs, Canadian Generic Pharmaceutical Association (CGPA), passed on the Committee steering wheel to [Archana Jatkar](#), Associate Secretary General, Indian Pharmaceutical Alliance (IPA), and [José Luis Cardenas](#), Sr. Dir Government Affairs & Market Access LATAM, Tevapharm,” Kox added.*

The incoming IGBA Chair, Jonathan Kimball, has been involved in the pharmaceutical industry for over 20 years and brings with him a wealth of experience in trade policy and international advocacy. *“It is an honour to be selected as IGBA’s Chair for 2023. The generic and biosimilar industries play a critical role in ensuring patients around the world have access to more affordable and quality-assured medicines. IGBA and its members, as well as the IGBA CEO Advisory Committee, are central to this effort, engaging with governments, regulators, and other stakeholders to promote an environment that ensures patients get access to the medicines they need, when they need them. I look forward to supporting this effort and building on the great success we had in 2022.”*

**About IGBA:** The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: [www.igbamedicines.org](http://www.igbamedicines.org)